Analyst Ratings for NewAmsterdam Pharma Co NV (NAMS)
NAMS Rating Summary
NAMS Price Target Summary
- Highest: $60.00 (Piper Sandler)
- Lowest: $45.00 (Guggenheim)
- Average: $51.70
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$51.70 (+63.2%)
* Over Last 12-Mos
Rating Score: 9.4 / 10
Percentile Rank: 90%
Avg. $ Target:
$51.70 (+63.2%)
* Over Last 12-Mos
Rating Score: 9.4 / 10
Percentile Rank: 90%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/18/2026 | Truist Securities | Srikripa Devarakonda | New Coverage | Buy (N/A) |
57.00 (N/A) |
30.60 (31.68) |
3.53% | Details |
| 10/20/2025 | H.C. Wainwright | Joseph Pantginis | New Coverage | Buy (N/A) |
52.00 (N/A) |
36.40 (31.68) |
-12.97% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
